Aligos Therapeutics Inc (ALGS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2023 | 09-2023 | 06-2023 | 03-2023 | 12-2022 | |
| Sales | 2,681 | 3,239 | 6,886 | 2,723 | 3,537 |
| Gross Profit | 2,681 | 3,239 | 6,886 | 2,723 | 3,537 |
| Operating Expenses | 28,678 | 22,310 | 26,027 | 26,641 | 26,219 |
| Operating Income | -25,997 | -19,071 | -19,141 | -23,918 | -22,682 |
| Other Income | -1,925 | 1,059 | 1,107 | 1,002 | 845 |
| Pre-tax Income | -27,922 | -18,012 | -18,034 | -22,916 | -21,837 |
| Income Tax | -30 | 29 | 757 | 39 | 49 |
| Net Income Continuous | -27,892 | -18,041 | -18,791 | -22,955 | -21,886 |
| Net Income | $-27,892 | $-18,041 | $-18,791 | $-22,955 | $-21,886 |
| EPS Basic Total Ops | 0.17 | -10.37 | -10.75 | -13.25 | -12.50 |
| EPS Basic Continuous Ops | 0.40 | -10.37 | -10.87 | -13.37 | -12.73 |
| EPS Diluted Total Ops | 0.17 | -10.37 | -10.75 | -13.25 | -12.50 |
| EPS Diluted Continuous Ops | 0.40 | -10.37 | -10.87 | -13.37 | -12.73 |
| EBITDA(a) | $-25,222 | $-18,390 | $-18,529 | $-23,341 | $-21,860 |